Sage Therapeutics

SAGE Therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare CNS disorders. Our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. To achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. SAGE’s lead program, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. SAGE’s robust chemistry platform has generated multiple new compounds that target the GABAA and NMDA receptors, which have demonstrated preclinical activity. SAGE Therapeutics is a private company launched in 2010 by an experienced team of R&D leaders, CNS experts and investors.
Type
Public
HQ
Cambridge, US
Founded
2010
Employees
62 (est)+94%

Key People at Sage Therapeutics

Stephen Kanes

Stephen Kanes

Chief Medical Officer
Thomas Anderson

Thomas Anderson

Chief Commercial Strategy Officer
Jim Doherty

Jim Doherty

Vice President of Pharmacology, Head of Biology
Jeffrey Jonas

Jeffrey Jonas

Chief Executive Officer
Albert J. Robichaud

Albert J. Robichaud

CSO
Kimi Iguchi

Kimi Iguchi

CFO

Sage Therapeutics Locations

Cambridge, US

Sage Therapeutics Metrics

Sage Therapeutics Summary

Founding Date

2010

Market capitalization

$1.83 B

Closing share price

$50.1

Sage Therapeutics Market Value History

Sage Therapeutics News

Sage Therapeutics Company Life

You may also be interested in